

New to Therapy
 Current Therapy

Patient Information	Prescriber Information
Patient Name: _____ Date of Birth: _____ Gender: _____ SS# _____ Address: _____ City: _____ State: _____ Zip: _____ Home Phone: _____ Work Phone: _____ Cell Phone: _____ E-mail: _____ Patient Weight: _____ kg/ lbs Patient Height: _____ in/ cm Please attach copy of front and back of patient's prescription ins. card(s) if applicable Insurance Company Name: _____ Insurance Company Phone: _____ Policy holder: _____ Policy holder Employer: _____ Relationship to Patient: _____ ID# _____ Group# _____ RxBIN: _____ RxPCN: _____	Practice/ Organization Name: _____ Physician Name: _____ Contact Person: _____ Contact's Phone: _____ Address: _____ City: _____ State: _____ Zip: _____ Office Phone#: _____ Office Fax#: _____ DEA# _____ NPI# _____ License#: _____ Medicaid UPIN#: _____ Physician Specialty: _____ Date Shipment Needed: _____ Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Prescriber <input type="checkbox"/> Other _____ Shipment Address: _____ Attn: _____ City: _____ State: _____ Zip: _____ <i>If shipped to the physician's office, physician accepts on behalf of patient for administration in office.</i>

Diagnosis and Clinical Information
Diagnosis (ICD-10): <input type="checkbox"/> J82 Pulmonary eosinophilia <input type="checkbox"/> J45.4 Moderate Persistent Asthma <input type="checkbox"/> J45.5 Severe Persistent Asthma <input type="checkbox"/> D72.119 Hypereosinophilic syndrome (HES) <input type="checkbox"/> M30.1 Eosinophilic Granulomatosis with Polyangiitis (EGPA) <input type="checkbox"/> J33.0 Polyp of the nasal cavity <input type="checkbox"/> J33.1 Polypoid sinus degeneration <input type="checkbox"/> J33.8 Other polyp of sinus <input type="checkbox"/> J33.9 Nasal polyp, unspecified <input type="checkbox"/> K20.0 Eosinophilic esophagitis (EOE) <input type="checkbox"/> Other: _____ Description: _____ Date of Diagnosis or Years with Disease: _____ Patients Allergies: _____ Latex allergy: <input type="checkbox"/> Yes <input type="checkbox"/> No Comorbidities: _____ Lab Results (attach if available): <input type="checkbox"/> Past positive skin or RAST test to perennial aeroallergen Pre-treatment: Serum IgE level: _____ IU/ML Testing date: _____ Serum eosinophils: _____ cells/mcL; Sputum eosinophils: _____ Testing date: _____ Previous and Current Medication Use: _____ <input type="checkbox"/> Short-acting beta agonist <input type="checkbox"/> Long-acting beta agonist <input type="checkbox"/> Antihistamines <input type="checkbox"/> Decongestants <input type="checkbox"/> Immunotherapy <input type="checkbox"/> Inhaled corticosteroids <input type="checkbox"/> Leukotriene modifiers <input type="checkbox"/> Oral steroids <input type="checkbox"/> Nasal steroids <input type="checkbox"/> Other: _____ Expected First Dose Date: _____ Injection training needed: <input type="checkbox"/> Yes <input type="checkbox"/> No EpiPen on hand for Patient: <input type="checkbox"/> Yes <input type="checkbox"/> No Shipment to Patient <input type="checkbox"/> Yes <input type="checkbox"/> No Shipment to Provider: <input type="checkbox"/> Yes <input type="checkbox"/> No Shipment Address: _____

Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.

<input type="checkbox"/> New to Therapy <input type="checkbox"/> Current Therapy

Patient Name: _____ **Patient Date of Birth:** _____

Prescriber Name: _____ **Office Phone:** _____ **Date:** _____

Prescriber Address: _____

Cinqair® (reslizumab) 100mg/10mL single-use vial
 3mg/kg Other: _____
 To be given by IV infusion once every 4 weeks by prescriber as directed.

Sterile Water for Injection
 To be used as directed to reconstitute **Xolair®** **Nucala®** vials
 Quantity: _____ vial(s) Refills: _____

Dupixent® (dupilumab) Prefilled Syringe Prefilled Pen
 100mg/0.67mL 200mg/1.14mL 300mg/2mL **Patient weight:** _____

Starter: Inject 600mg SC day 1 then 300mg SC on day 15
 Starter: Inject 400mg SC on day 1 then 200mg SC on day 15
 Starter: Inject 600mg SC day 1 then 300mg SC every 4 weeks
 Maintenance: Inject 300mg SC every 2 weeks
 Maintenance: Inject 200mg SC every 2 weeks
 Maintenance: Inject 100mg SC every 2 weeks
 Maintenance: Inject 300mg SC every 4 weeks
 Maintenance: Inject 300mg SC every week
 Other: _____

EpiPen **EpiPen Jr**
 Use as directed for anaphylaxis
 Quantity: 2 Pens Refills: _____

****If additional ancillary supplies needed, please send additional prescriptions.****

Nucala® (mepolizumab) 100mg/mL Vial 100mg/mL Prefilled Syringe
 100mg/mL Auto-Injector 40mg/0.4mL Prefilled Syringe
 Inject 100mg subcutaneously once every 4 weeks.
 Inject 40mg subcutaneously once every 4 weeks.

Xolair® (omalizumab) 75mg Prefilled syringe 150mg Prefilled syringe 150mg vial
 To be injected subcutaneously once every 4 weeks as directed:
 75 mg 150 mg 225 mg 300 mg Other: _____
 To be injected subcutaneously once every 2 weeks as directed:
 225 mg 300 mg 375 mg Other: _____
 Other: _____

Dispense Quantity: _____ **Refills:** _____

Prescriber Signature: X _____

If Brand required "Dispense as Written" must be handwritten.